Development of technology and mobile diagnostic apparatus based on a lab-on-track solution to detect infectious diseases (Q78118): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: summary (P836): The project concerns the R & D work and the pre-implementation work to lead to the development and commercialisation of an innovative international (molecular diagnostic) diagnostic apparatus for detection of dangerous infectious diseases in the period 2019-2022:1/Chlamydia tracheitis 2/Chlamydophila pneumoniae 3/Mycoplasma OF pneumoniae 4/Neisseria meningitidis 5/Neisseria A solution is to be based on the author (SNAAT) and the use of an insu...) |
(Created claim: summary (P836): The project concerns R & D and pre-implementation work, which will lead to the development and commercialisation of internationally innovative diagnostic apparatus (Molecular Diagnostics) for the detection of pathogens of dangerous infectious diseases between 2019 and 2022: 1/Chlamydia trachomatis 2/Chlamydophila pneumoniae 3/Mycoplasma pneumoniae 4/Neisseria meningitidis 5/Neisseria gonorrhoeae 6/MRSA The solution is to be based on the propriet...) |
||||||||||||||
| Property / summary | |||||||||||||||
The project concerns R & D and pre-implementation work, which will lead to the development and commercialisation of internationally innovative diagnostic apparatus (Molecular Diagnostics) for the detection of pathogens of dangerous infectious diseases between 2019 and 2022: 1/Chlamydia trachomatis 2/Chlamydophila pneumoniae 3/Mycoplasma pneumoniae 4/Neisseria meningitidis 5/Neisseria gonorrhoeae 6/MRSA The solution is to be based on the proprietary GENOMTEC technology called SNAAT (Simplified Nucleic Acid Amplification Technology) taking into account laboratory-on-Chip solutions. The diagnostic process will be performed using a maintenance-free reaction card and control device. DIAGNOSTIC EQUIPMENT WILL BE THE FIRST ON THE WORLD MARKET, MOBILE, ALLOWING FAST AND PRECISE MOLECULAR TESTS ANYWHERE, BY MEDICAL PERSONNEL, WITHOUT THE NEED FOR LABORATORY EXPERIENCE (WHILE MAINTAINING THE COMPETITIVENESS OF THE PRODUCT PRICE). AS A RESULT, IT WILL BE POSSIBLE TO DETECT DISEASES EARLY AND USE APPROPRIATE THERAPIES. Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26 (English) | |||||||||||||||
| Property / summary: The project concerns R & D and pre-implementation work, which will lead to the development and commercialisation of internationally innovative diagnostic apparatus (Molecular Diagnostics) for the detection of pathogens of dangerous infectious diseases between 2019 and 2022: 1/Chlamydia trachomatis 2/Chlamydophila pneumoniae 3/Mycoplasma pneumoniae 4/Neisseria meningitidis 5/Neisseria gonorrhoeae 6/MRSA The solution is to be based on the proprietary GENOMTEC technology called SNAAT (Simplified Nucleic Acid Amplification Technology) taking into account laboratory-on-Chip solutions. The diagnostic process will be performed using a maintenance-free reaction card and control device. DIAGNOSTIC EQUIPMENT WILL BE THE FIRST ON THE WORLD MARKET, MOBILE, ALLOWING FAST AND PRECISE MOLECULAR TESTS ANYWHERE, BY MEDICAL PERSONNEL, WITHOUT THE NEED FOR LABORATORY EXPERIENCE (WHILE MAINTAINING THE COMPETITIVENESS OF THE PRODUCT PRICE). AS A RESULT, IT WILL BE POSSIBLE TO DETECT DISEASES EARLY AND USE APPROPRIATE THERAPIES. Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26 (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The project concerns R & D and pre-implementation work, which will lead to the development and commercialisation of internationally innovative diagnostic apparatus (Molecular Diagnostics) for the detection of pathogens of dangerous infectious diseases between 2019 and 2022: 1/Chlamydia trachomatis 2/Chlamydophila pneumoniae 3/Mycoplasma pneumoniae 4/Neisseria meningitidis 5/Neisseria gonorrhoeae 6/MRSA The solution is to be based on the proprietary GENOMTEC technology called SNAAT (Simplified Nucleic Acid Amplification Technology) taking into account laboratory-on-Chip solutions. The diagnostic process will be performed using a maintenance-free reaction card and control device. DIAGNOSTIC EQUIPMENT WILL BE THE FIRST ON THE WORLD MARKET, MOBILE, ALLOWING FAST AND PRECISE MOLECULAR TESTS ANYWHERE, BY MEDICAL PERSONNEL, WITHOUT THE NEED FOR LABORATORY EXPERIENCE (WHILE MAINTAINING THE COMPETITIVENESS OF THE PRODUCT PRICE). AS A RESULT, IT WILL BE POSSIBLE TO DETECT DISEASES EARLY AND USE APPROPRIATE THERAPIES. Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26 (English) / qualifier | |||||||||||||||
point in time: 14 October 2020
| |||||||||||||||
Revision as of 11:14, 14 October 2020
Project in Poland financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Development of technology and mobile diagnostic apparatus based on a lab-on-track solution to detect infectious diseases |
Project in Poland financed by DG Regio |
Statements
8,912,385.14 zloty
0 references
12,210,584.19 zloty
0 references
72.99 percent
0 references
1 January 2019
0 references
30 November 2022
0 references
GENOMTEC SPÓŁKA AKCYJNA
0 references
51°7'34.7"N, 16°58'41.5"E
0 references
Projekt dotyczy prac B+R oraz prac przedwdrożeniowych, które mają doprowadzić do opracowania i komercjalizacji w latach 2019-2022 innowacyjnej w skali międzynarodowej aparatury diagnostycznej (z obszaru diagnostyki molekularnej) przeznaczonej do detekcji patogenów groźnych chorób zakaźnych: 1/ Chlamydia trachomatis 2/ Chlamydophila pneumoniae 3/ Mycoplasma pneumoniae 4/ Neisseria meningitidis 5/ Neisseria gonorrhoeae 6/ MRSA Rozwiązanie ma opierać się na autorskiej technologii GENOMTEC pod nazwą SNAAT (Simplified Nucleic Acid Amplification Technology) z uwzględnieniem rozwiązań typu Laboratory-on-Chip (LOC) I wykorzystaniu techniki izotermalnej LAMP. Proces diagnostyczny przebiegać będzie przy użyciu bezobsługowej karty reakcyjnej oraz urządzenia sterującego. APARATURA DIAGNOSTYCZNA BĘDZIE PIERWSZYM NA RYNKU ŚWIATOWYM, MOBILNYM ROZWIĄZANIEM UMOŻLIWIAJĄCYM SZYBKIE I PRECYZYJNE WYKONYWANIE BADAŃ MOLEKULARNYCH W KAŻDYM MIEJSCU, PRZEZ PERSONEL MEDYCZNY, BEZ KONIECZNOŚCI DOŚWIADCZENIA LABORATORYJNEGO (PRZY ZACHOWANIU KONKURENCYJNOŚCI CENOWEJ PRODUTKU). DZIĘKI TEMU MOŻLIWE BĘDZIE WCZESNE WYKRYCIE CHORÓB I ZASTOSOWANIE ODPOWIEDNIEJ TERAPII. Numer_referencyjny_programu_pomocowego: SA.41471(2015/X) Przeznaczenie_pomocy_publicznej: art. 25 rozporządzenia KE nr 651/2014 z dnia 17 czerwca 2014 r. uznające niektóre rodzaje pomocy za zgodne z rynkiem wewnętrznym w stosowaniu art. 107 i 108 Traktatu (Dz. Urz. UE L 187/1 z 26 (Polish)
0 references
The project concerns R & D and pre-implementation work, which will lead to the development and commercialisation of internationally innovative diagnostic apparatus (Molecular Diagnostics) for the detection of pathogens of dangerous infectious diseases between 2019 and 2022: 1/Chlamydia trachomatis 2/Chlamydophila pneumoniae 3/Mycoplasma pneumoniae 4/Neisseria meningitidis 5/Neisseria gonorrhoeae 6/MRSA The solution is to be based on the proprietary GENOMTEC technology called SNAAT (Simplified Nucleic Acid Amplification Technology) taking into account laboratory-on-Chip solutions. The diagnostic process will be performed using a maintenance-free reaction card and control device. DIAGNOSTIC EQUIPMENT WILL BE THE FIRST ON THE WORLD MARKET, MOBILE, ALLOWING FAST AND PRECISE MOLECULAR TESTS ANYWHERE, BY MEDICAL PERSONNEL, WITHOUT THE NEED FOR LABORATORY EXPERIENCE (WHILE MAINTAINING THE COMPETITIVENESS OF THE PRODUCT PRICE). AS A RESULT, IT WILL BE POSSIBLE TO DETECT DISEASES EARLY AND USE APPROPRIATE THERAPIES. Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26 (English)
14 October 2020
0 references
Identifiers
POIR.01.01.01-00-0563/18
0 references